CBD (Epidiolex) has demonstrated efficacy and an acceptable safety profile for seizures in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, though its mechanisms are not fully understood and several clinical challenges remain.
Neurologists, epilepsy specialists, patients and families managing treatment-resistant epilepsy.
CBD is FDA-approved for three rare epileptic encephalopathies
What the researchers found
Randomized clinical trials support CBD for seizures in three rare epileptic encephalopathies: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. CBD shows broad-spectrum efficacy across seizure types and possesses anti-inflammatory and neuroprotective properties. Key challenges include limited understanding of pharmacodynamics, complex drug interactions, and lack of expert dosing guidelines.
Why it matters
For families dealing with severe childhood epilepsies that resist standard medications, CBD represents the first plant-derived cannabinoid to receive FDA approval. This review maps both its promise and its unresolved clinical challenges.
The numbers in context
FDA approved in 2018. Three approved indications: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex. Multimodal mechanisms including non-cannabinoid pathways.
How the study worked
Comprehensive narrative review of preclinical and clinical evidence for CBD in refractory epilepsy, covering mechanisms, clinical trials, pharmacokinetics, and outstanding challenges.
What this study cannot tell us
Narrative review without systematic methodology. Some included trial data are industry-sponsored. Long-term seizure freedom data are limited. CBD pharmacokinetics are complex with significant drug interactions.
How to read the evidence
Comprehensive review drawing on randomized clinical trial data and preclinical evidence. FDA approval supports strong evidence base.
When this study was published
Published in 2023.
The bigger picture
The approval of Epidiolex was a landmark moment for cannabinoid medicine, establishing that at least one cannabis-derived compound can meet the rigorous standards of pharmaceutical regulation. The remaining challenges around drug interactions and dosing guidelines highlight how much work remains.
Questions still open
- Will long-term use of CBD maintain seizure reduction or develop tolerance?
- Could CBD be effective for other epilepsy types beyond the three approved indications?
Common questions
What epilepsies is CBD approved for?
What are the challenges with CBD for epilepsy?
Read the original research
Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Experimental neurology, 359, 114237
Citation
Reddy, Doodipala Samba. (2023). Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.. Experimental neurology, 359, 114237. https://doi.org/10.1016/j.expneurol.2022.114237
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk